Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 16/20 | 0.62 |
| ▸ | FAAH | O00519 | 6/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331305 | 0.83 | MGLL (0.68) | MGLLFAAHHSP90AA1TDP1BCHE | |
| SCHEMBL9718403 | 0.83 | MGLL (0.68) | MGLLFAAHHSP90AA1TDP1BCHE | |
| SCHEMBL1632277 | 0.79 | CA1 (0.63) | MGLLFAAHHSP90AA1TDP1PKM | |
| SCHEMBL28752490 | 0.79 | MGLL (0.62) | MGLLFAAHHSP90AA1TDP1BCHE | |
| SCHEMBL1830817 | 0.79 | MGLL (0.62) | MGLLFAAHHSP90AA1TDP1BCHE | |
| SCHEMBL32665177 | 0.79 | MGLL (0.62) | MGLLFAAHHSP90AA1TDP1BCHE | |
| SCHEMBL95324 | 0.79 | MGLL (1.00) | MGLLFAAHHSP90AA1TDP1BCHE | |
| SCHEMBL11384686 | 0.79 | MGLL (0.56) | MGLLFAAHHSP90AA1TDP1BCHE | |
| SCHEMBL11388703 | 0.79 | MGLL (0.56) | MGLLFAAHHSP90AA1TDP1BCHE | |
| SCHEMBL11594889 | 0.78 | MGLL (0.60) | MGLLFAAHHSP90AA1TDP1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651902-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024155747-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | THERAPHARM GMBH | 2009-06-25 | — | — | US | disclosed |
| EP-1942949-A1 | METHOD FOR THE SYNTHESIS OF PENTAPENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIO-CONJUGATES PREPARATION BY A COVALENT BINDING OF THEREOF | Therapharm GmbH (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007028639-A1 | METHOD FOR THE SYNTHESIS OF PENTAPENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIO-CONJUGATES PREPARATION BY A COVALENT BINDING OF THEREOF | THERAPHARM GMBH (CH) | 2007-03-15 | — | — | WO | disclosed |
| EP-0025015-A2 | Process for glueing a substrate coated with a zinciferous organic material | CIBA-GEIGY AG (CH) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | C5, C3AR1, SPR | MGLL 4807/4885FAAH 4005/4885HSP90AA1 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.